Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.74 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.74 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.74 |
| ▸ | APP | P05067 | 1/20 | 0.72 |
| ▸ | RXRA | P19793 | 1/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LIPE | Q05469 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416387 | 1.00 | HTR1A (0.74) | HTR1AADRA1DADRA1AADRA1BAPP | |
| Ammonia Solution, Strong SCHEMBL2063054 | 0.98 | HTR1A (0.72) | HTR1AADRA1DADRA1AADRA1BAPP | |
| SCHEMBL906201 | 0.92 | HTR1A (0.66) | HTR1AADRA1DADRA1AADRA1BAPP | |
| Ethylamine SCHEMBL28464910 | 0.91 | HTR1A (0.64) | HTR1AADRA1DADRA1AADRA1BAPP | |
| SCHEMBL339812 | 0.89 | MAPT (0.71) | HTR1AADRA1DADRA1AADRA1BAPP | |
| SCHEMBL9474602 | 0.88 | APP (0.69) | HTR1AADRA1DADRA1AADRA1BAPP | |
| SCHEMBL9615215 | 0.88 | MRGPRX4 (0.69) | HTR1AADRA1DADRA1AADRA1BAPP | |
| SCHEMBL1639591 | 0.86 | HTR1A (0.58) | HTR1AADRA1DADRA1AADRA1BAPP | |
| SCHEMBL3232989 | 0.86 | HTR1A (0.58) | HTR1AADRA1DADRA1AADRA1BAPP | |
| SCHEMBL15264273 | 0.84 | APP (0.69) | HTR1AADRA1DADRA1AADRA1BAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115980372-A | High-specificity high-density lipoprotein PEG-cyclodextrin sulfate system additive | 东软威特曼生物科技(南京)有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-110054588-A | A kind of synthetic method of 6- benzyloxy -7- methoxyl group -3,4- dihydro-isoquinoline | 江苏省原子医学研究所 | 2019-07-26 | — | — | CN | claimed |
| CN-116396270-A | Benzo [ b ] selenophen STING agonist fluorescent probe molecule and application thereof | 中国药科大学 | 2023-07-07 | — | — | CN | disclosed |
| US-20190343754-A1 | PROCESS FOR TREATING KERATIN FIBRES WITH A PHOTOCROSSLINKABLE POLYVINYL ALCOHOL | L'OREAL (FR) | 2019-11-14 | — | — | US | disclosed |
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-07-27 | — | — | US | disclosed |
| US-9580430-B2 | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150246923-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-03 | — | — | US | disclosed |
| US-20140336259-A1 | PHENOLIC COMPOUNDS WITH ANTIOXIDANT AND ANTI-CANCER PROPERTIES, ANALOGS AND SYNTHESIS THEREOF | FEDERATION DES PRODUCTEURS ACERICOLES DU QUEBEC (CA) | 2014-11-13 | — | — | US | disclosed |
| US-20140336259-A1 | PHENOLIC COMPOUNDS WITH ANTIOXIDANT AND ANTI-CANCER PROPERTIES, ANALOGS AND SYNTHESIS THEREOF | FEDERATION DES PRODUCTEURS ACERICOLES DU QUEBEC (CA) | 2014-11-13 | — | — | US | disclosed |
| CN-102124012-B | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | TIBOTEC PHARM LTD | 2014-07-02 | — | — | CN | disclosed |
| EP-1994004-B9 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-0912562-A1 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1999-05-06 | — | — | EP | disclosed |
| US-5723489-A | ADRENERGIC BLOCKING AGENTS OR STIMULANTS FOR GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-03-03 | — | — | US | disclosed |
| WO-1998003505-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-29 | — | — | WO | disclosed |
| EP-0634401-B1 | MDR reversal agents | AMERICAN CYANAMID CO (US) | 1997-08-13 | — | — | EP | disclosed |
| US-5639887-A | MULTIDRUG RESISTANT CELLS; INCREASE CELL SENSITIVITY TO ANTICANCER AGENTS | AMERICAN CYANAMID COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| US-5561141-A | POTENTIATE ACTIVITY OF ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1996-10-01 | — | — | US | disclosed |
| US-5550149-A | SULFUR-CONTAINING COMPOUNDS THAT ARE EFFECTIVE IN POTENTIATING THE ACTIVITY OF CHEMOTHERAPEUTIC ANTI-CANCER AGENTS BY INCREASING SENSITIVITY OF MULTI-DRUG RESISTANT CELLS | AMERICAN CYANAMID COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| US-5387685-A | MDR reversal agents | AMERICAN CYANAMID COMPANY | 1995-02-07 | — | — | US | disclosed |
| EP-0634401-A1 | MDR reversal agents | AMERICAN CYANAMID COMPANY (US) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HTR1A 123/4885ADRA1D 135/4885ADRA1A 132/4885 |
| US-20150246923-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HTR1A 123/4885ADRA1D 135/4885ADRA1A 132/4885 |
| US-20140336259-A1 | PHENOLIC COMPOUNDS WITH ANTIOXIDANT AND ANTI-CANCER PROPERTIES, ANALOGS AND SYNTHESIS THEREOF | GPX1, CAT, GPX4 | HTR1A 4730/4885ADRA1D 4013/4885ADRA1A 3852/4885 |
| US-20190343754-A1 | PROCESS FOR TREATING KERATIN FIBRES WITH A PHOTOCROSSLINKABLE POLYVINYL ALCOHOL | KRT18, CUTA, DSG1 | HTR1A 4447/4885ADRA1D 3332/4885ADRA1A 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.